Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Pharmaceuticals

Real-time Euronext Bruxelles 08:48:19 2024-04-15 am EDT 5-day change 1st Jan Change
12.4 EUR +1.64% Intraday chart for Hyloris Pharmaceuticals SA -0.40% -2.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 CI
Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada MT
Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse MT
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4% MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US MT
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis CI
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus CI
Hyloris Pharmaceuticals Wins US FDA's Orphan Drug Designation for Leukemia Treatment MT
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals CI
Hyloris Pharmaceuticals Partner Gets US FDA Nod for Warts Gel MT
Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada CI
Hyloris Pharmaceuticals’ Pain Relief Drug Gets US FDA Approval; Shares Jump MT
Hyloris Pharma wins US FDA approval for pain treatment RE
Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV CI
Transcript : Hyloris Pharmaceuticals SA, H1 2023 Earnings Call, Sep 07, 2023
Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-JUN-2023. CI
Hyloris Pharmaceuticals Wins EUR1 Million Grant to Develop Idiopathic Rhinitis Treatment MT
Hyloris Partner Submits Additional Data to US FDA for Non-opioid Pain Treatment MT
Transcript : Hyloris Pharmaceuticals SA, 2022 Earnings Call, Mar 16, 2023
Chart Hyloris Pharmaceuticals SA
More charts
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.2 EUR
Average target price
21.55 EUR
Spread / Average Target
+76.64%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. HYL Stock
  4. News Hyloris Pharmaceuticals SA
  5. Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse